GlassScriptPhysician profile
Ryan J Mcdonough
NPI 1568635357
$6,564.96
in general payments reported to CMS, 2019-2025
14 companies · $2,945 in 2025
The $2,945 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $111 · 2021: $216 · 2022: $265 · 2023: $269 · 2024: $2,592 · 2025: $2,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,261 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,240 · Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,260.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,240.00 |
| Food and Beverage | $1,306.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,715.15 | 2025 | Xience Skypoint, Jot Dx, Cardiomems |
| Sanofi-Aventis U.S. LLC | $2,240.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $484.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $428.93 | 2020-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $139.24 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $122.57 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $113.34 | 2019-2021 | |
| Amgen INC. | $91.69 | 2021-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $65.20 | 2019 | |
| Cardiovascular Systems INC. | $45.28 | 2019-2023 | Diamondback Coronary |
| Abiomed | $43.65 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $23.72 | 2020-2021 | |
| Braemar Manufacturing, LLC | $21.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.